

Amendments to the Claims:

This listing of claims will replace all prior listings and versions of claims in this application.

1-10. (Cancelled)

11. (Currently Amended) An antibody which specifically binds to a polypeptide of SEQ ID NO:2120 according to claim 8, wherein the polypeptide is shown as Figure 5242 (SEQ ID NO:2120), wherein said antibody modulates activity of T cells.

12. (Previously presented) The antibody of claim 11, wherein said antibody is a monoclonal antibody, a humanized antibody or a single-chain antibody.

13. (Currently Amended) A composition of matter comprising (a) a polypeptide of claim 8, (b) an agonist of said polypeptide, (c) an antagonist of said polypeptide, or (d) an antibody of Claim 11 that binds to said polypeptide, in combination with a carrier, wherein the polypeptide is shown as Figure 5242 (SEQ ID NO:2120).

14. (Previously presented) The composition of matter of claim 13, wherein said carrier is a pharmaceutically acceptable carrier.

15. (Currently amended) The composition of matter of claim 14 comprising a therapeutically effective amount of (a), (b), (c) or (d) the antibody of Claim 11.

16. (Currently Amended) An article of manufacture, comprising:
a container;
a label on said container; and
a composition of matter of Claim 15 comprising (a) a polypeptide of claim 8, (b) an agonist of said polypeptide, (c) an antagonist of said polypeptide, or (d) an antibody that binds to said polypeptide, contained within said container, wherein the polypeptide is shown as Figure 5242 (SEQ ID NO:2120) and wherein label on said container indicates that said composition of matter can be used for treating an immune related disease.

17-27. (Cancelled)